Last kr2.05 DKK
Change Today -0.03 / -1.44%
Volume 118.6K
BIOPOR On Other Exchanges
Symbol
Exchange
Copenhagen
As of 11:01 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

bioporto a/s (BIOPOR) Snapshot

Open
kr2.07
Previous Close
kr2.08
Day High
kr2.09
Day Low
kr2.00
52 Week High
03/11/14 - kr4.80
52 Week Low
10/7/13 - kr1.07
Market Cap
241.6M
Average Volume 10 Days
286.7K
EPS TTM
kr-0.17
Shares Outstanding
117.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOPORTO A/S (BIOPOR)

Related News

No related news articles were found.

bioporto a/s (BIOPOR) Related Businessweek News

No Related Businessweek News Found

bioporto a/s (BIOPOR) Details

BioPorto A/S, an in-vitro diagnostics company, develops and markets diagnostic tests and antibodies for the healthcare professionals in clinical and research settings. Its products include neutrophil gelatinase-associated lipocalin (NGAL) Test for the diagnosis of acute kidney injury; and NGAL enzyme-linked immunosorbent assay (ELISA) kit for the in vitro determination of human NGAL in urine, plasma, serum, tissue extracts, or culture media. The company also provides activated protein C and protein C inhibitor complex (APC-PCI) ELISA kit that measures the APC-PCI in human plasma for the treatment of sepsis; and mannan-binding lectin (MBL) oligomer ELISA kit to determine oligomerized MBL in human serum or heparin plasma for the assessment of primary immunodeficiency. In addition, it markets various monoclonal antibodies under the AntibodyShop name, including antibodies for the research in the areas of NGAL; peptide hormones, including type-2 diabetes/obesity; immunology; and microbiology. The company was founded in 2000 and is based in Gentofte, Denmark.

24 Employees
Last Reported Date: 08/8/14
Founded in 2000

bioporto a/s (BIOPOR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioporto a/s (BIOPOR) Key Developments

BioPorto A/S Announces Unaudited Group Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Maintains Earnings Guidance for 2014

BioPorto A/S announced unaudited group earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net revenues of DKK 4,485,000 against DKK 4,257,000 a year ago. Loss before interest and taxes were DKK 5,682,000 against DKK 4,510,000 a year ago. Loss before taxes was DKK 5,698,000 against DKK 5,125,000 a year ago. Net loss/comprehensive loss was DKK 4,645,000 or DKK 0.04 per share against DKK 5,125,000 or DKK 0.08 per share a year ago. Cash outflow from operating activities was DKK 4,019,000 against DKK 4,631,000 a year ago. For the six months period, the company reported net revenues of DKK 9,236,000 against DKK 7,267,000 a year ago. Loss before interest and taxes were DKK 9,306,000 against DKK 9,604,000 a year ago. Loss before taxes was DKK 9,310,000 against DKK 10,756,000 a year ago. Net loss/comprehensive loss was DKK 8,257,000 or DKK 0.07 per share against DKK 10,756,000 or DKK 0.17 per share a year ago. Cash outflow from operating activities was DKK 9,433,000 against DKK 9,846,000 a year ago. Purchase of intangible assets was DKK 265,000. Purchase of tangible assets was DKK 542,000 against DKK 27,000 a year ago. The company maintained earnings guidance for 2014. For the year, the company expects to generate revenue of around DKK 19 million to DKK 23 million, equivalent to a growth rate of 15% to 40%. A loss of around DKK 10 million to DKK 14 million is expected.

BioPorto A/S, Q2 2014 Earnings Call, Aug 08, 2014

BioPorto A/S, Q2 2014 Earnings Call, Aug 08, 2014

BioPorto A/S Reports Earnings Results or the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

BioPorto A/S reported earnings results or the first quarter ended March 31, 2014. For the quarter, net revenues were DKK 4.751 million against DKK 3.010 million a year ago. Net loss from operating activities were DKK 3.624 million against DKK 5.094 million a year ago. Loss before tax was DKK 3.612 million against DKK 5.631 million a year ago. Net loss for the period was DKK 3.612 million or DKK 0.03 per share against DKK 5.631 million or DKK 0.09 per share a year ago. Cash flow by operation was DKK 5.414 million against DKK 5.214 million a year ago. Cash invested in property, plant and equipment was DKK 0.361 million against DKK 0.027 million a year ago. For 2014, the company expects to generate revenue of around DKK 19-23 million, equivalent to a growth rate of 15-40%. The company also expects a loss of around DKK 10-14 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOPOR:DC kr2.05 DKK -0.03

BIOPOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr112.00 DKK -2.50
Chimerix Inc $25.54 USD +0.06
Emergent Biosolutions Inc $24.90 USD +0.03
GlaxoSmithKline PLC 1,475 GBp +11.50
View Industry Companies
 

Industry Analysis

BIOPOR

Industry Average

Valuation BIOPOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOPORTO A/S, please visit www.bioporto.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.